Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3058262 | 1.00 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CGAACYP3A4 | |
| SCHEMBL3058266 | 1.00 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CGAACYP3A4 | |
| SCHEMBL3058264 | 1.00 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CGAACYP3A4 | |
| SCHEMBL4955686 | 1.00 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CGAACYP3A4 | |
| SCHEMBL5534012 | 1.00 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CGAACYP3A4 | |
| SCHEMBL5530647 | 1.00 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CGAACYP3A4 | |
| SCHEMBL5534015 | 1.00 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CGAACYP3A4 | |
| SCHEMBL2624064 | 1.00 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CGAACYP3A4 | |
| SCHEMBL5530641 | 1.00 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CGAACYP3A4 | |
| SCHEMBL7898346 | 0.95 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CGAACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048862-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-20090269305-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269305-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | ADRB3 4326/4885ADRA2B 4470/4885ADRA2C 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.